Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07548450 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
A Phase 2 study, sponsored by University of Utah.
- Not yet
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT07548450 is a Phase 2 study that has not yet begun recruiting, run by University of Utah. The registered enrollment target is 25 participants.
The verdict
NCT07548450, a Phase 2 study, has not yet begun recruiting, sponsored by University of Utah.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
Interventions
- DRUG Mosunetuzumab
- DRUG Pirtobrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06 |
| Est. Completion | 2035-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07548450
The ClinicalTrials.gov registry entry for NCT07548450 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mosunetuzumab is the first listed.
NCT07548450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07548450 about?
NCT07548450 is a clinical study titled "Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)". The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
What is the current status of trial NCT07548450?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-06. Estimated completion is 2035-06.
What interventions are being tested in trial NCT07548450?
The interventions under investigation include: Mosunetuzumab (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT07548450?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.